• Algeta ASA, of Oslo, Norway, said partner Bayer AG, of Leverkusen, Germany, submitted a marketing authorization application to the European Medicines Agency for Alpharadin (radium-223 dichloride) for the treatment of castration-resistant prostate cancer patients with bone metastases. The submission triggers a €50 million (US$65.7 million) milestone payment under the firms' 2009 agreement, and it is based on positive data from the Phase III ALSYMPCA study, in which Alpharadin significantly increased overall survival by 44 percent.